Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • The use of dual atazanavir/ritonavir plus lamivudine therapy for maintenance of viral suppression has been evaluated in several trials
    • SALT: dual boosted atazanavir plus lamivudine was noninferior to triple therapy of boosted atazanavir plus 2 NRTIs for maintenance of virologic suppression through 48 weeks[Perez-Molina 2015]
      • Approximately one half of patients in both arms had grade 3/4 hyperbilirubinemia

Action required